Indian pharmaceutical companies are exporting the powerful opioid tapentadol to street pharmacies across West Africa [1, 2].

This flow of narcotics is aggravating a regional opioid addiction crisis as a potent controlled substance enters the unregulated market. Because the drugs are sold as ordinary painkillers, many consumers are unaware of the high risk of dependency associated with the medication [1, 3].

The exports occur on a monthly basis [2]. These shipments target street-level pharmacies where regulatory oversight is often minimal, allowing the drugs to be distributed widely without strict medical prescriptions [1, 2].

Industry sources said that the primary driver for these exports is profit. By marketing the opioids as standard pain relief, exporters can move large volumes of tapentadol into markets with high demand and low enforcement [1, 3].

West African nations are now facing the consequences of this supply chain. The influx of tapentadol has led to an increase in addiction cases across the region, a trend that mirrors previous opioid epidemics seen in other parts of the world [1, 2].

Local authorities and health officials said they are struggling to contain the spread. The ease of access to these medications via street pharmacies means that the drug is reaching a broad demographic, including those who would not typically seek out illicit narcotics [1, 3].

“Indian pharmaceutical companies are exporting the powerful opioid tapentadol to street pharmacies across West Africa”

The situation highlights a critical gap in international pharmaceutical regulation and border control. When potent opioids are mislabeled or under-regulated during export, it allows pharmaceutical firms to bypass safety protocols and profit from the resulting public health crises in developing regions. This creates a systemic vulnerability where West African healthcare infrastructures must manage a surge in addiction without the tools to stop the source of the supply.